REVERAGEN BIOPHARMA Trademark

Trademark Overview


On Friday, September 5, 2014, a trademark application was filed for REVERAGEN BIOPHARMA with the United States Patent and Trademark Office. The USPTO has given the REVERAGEN BIOPHARMA trademark a serial number of 86386224. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Monday, August 9, 2021. This trademark is owned by ReveraGen Biopharma, Inc.. The REVERAGEN BIOPHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development
reveragen biopharma

General Information


Serial Number86386224
Word MarkREVERAGEN BIOPHARMA
Filing DateFriday, September 5, 2014
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateMonday, August 9, 2021
Registration Number4742704
Registration DateTuesday, May 26, 2015
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, March 10, 2015

Trademark Statements


Description of MarkThe mark consists of The mark consists of the words "ReveraGen" and "BioPharma" with a blue capitalized "R", and the letters "evera" in blue lower case, with a green capitalized "G", and the letter "en" in green lower case. The word "ReveraGen" has shadow reflections below the letters. The mark consists of the word "BioPharma" in blue, with a capitalized "B" and "P".
Indication of Colors claimedThe color(s) blue and green is/are claimed as a feature of the mark.
NOT AVAILABLE"BIOPHARMA"
Goods and ServicesPharmaceutical research and development

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 16, 2014
Primary Code042
First Use Anywhere DateTuesday, March 15, 2011
First Use In Commerce DateMonday, January 13, 2014

Trademark Owner History


Party NameReveraGen Biopharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Party NameReveraGen Biopharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20910

Party NameReveraGen Biopharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20910

Trademark Events


Event DateEvent Description
Tuesday, September 16, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 17, 2014ASSIGNED TO EXAMINER
Tuesday, September 9, 2014NEW APPLICATION ENTERED
Wednesday, December 17, 2014PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, February 3, 2015ASSIGNED TO LIE
Tuesday, February 3, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, December 17, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 17, 2014NON-FINAL ACTION WRITTEN
Wednesday, December 17, 2014NON-FINAL ACTION E-MAILED
Wednesday, December 17, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 6, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 6, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 6, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 14, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 18, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 10, 2015PUBLISHED FOR OPPOSITION
Tuesday, March 10, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, April 8, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 26, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, May 26, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, October 11, 2016TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 9, 2021TEAS SECTION 8 & 15 RECEIVED
Monday, August 9, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, August 9, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sunday, May 26, 2024COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Monday, August 9, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED